- Home
- KXIN vs NXTC Comparison
KXIN vs NXTC Comparison
Compare KXIN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- NXTC
- Stock Information
- Founded
- KXIN 2015
- NXTC 2015
- Country
- KXIN China
- NXTC United States
- Employees
- KXIN N/A
- NXTC N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- NXTC Health Care
- Exchange
- KXIN Nasdaq
- NXTC Nasdaq
- Market Cap
- KXIN 13.0M
- NXTC 13.9M
- IPO Year
- KXIN N/A
- NXTC 2019
- Fundamental
- Price
- KXIN $0.95
- NXTC $0.48
- Analyst Decision
- KXIN
- NXTC Strong Buy
- Analyst Count
- KXIN 0
- NXTC 2
- Target Price
- KXIN N/A
- NXTC $3.50
- AVG Volume (30 Days)
- KXIN 205.6K
- NXTC 141.9K
- Earning Date
- KXIN 01-01-0001
- NXTC 05-01-2025
- Dividend Yield
- KXIN N/A
- NXTC N/A
- EPS Growth
- KXIN N/A
- NXTC N/A
- EPS
- KXIN N/A
- NXTC N/A
- Revenue
- KXIN N/A
- NXTC N/A
- Revenue This Year
- KXIN N/A
- NXTC N/A
- Revenue Next Year
- KXIN N/A
- NXTC N/A
- P/E Ratio
- KXIN N/A
- NXTC N/A
- Revenue Growth
- KXIN N/A
- NXTC N/A
- 52 Week Low
- KXIN $0.64
- NXTC $0.22
- 52 Week High
- KXIN $29.54
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- KXIN 48.41
- NXTC 52.82
- Support Level
- KXIN $0.93
- NXTC $0.46
- Resistance Level
- KXIN $1.02
- NXTC $0.52
- Average True Range (ATR)
- KXIN 0.07
- NXTC 0.04
- MACD
- KXIN 0.00
- NXTC 0.00
- Stochastic Oscillator
- KXIN 20.69
- NXTC 54.50
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.